Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
Provided By GlobeNewswire
Last update: Mar 31, 2025
Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled
Read more at globenewswire.comFORTRESS BIOTECH INC - FBIO 9 3/8 PERP
NASDAQ:FBIOP (6/17/2025, 10:43:13 AM)
8.75
+0.07 (+0.81%)
NASDAQ:FBIO (6/17/2025, 11:07:25 AM)
1.85
+0.01 (+0.54%)
Find more stocks in the Stock Screener
